Bone Therapeutics provides update on the progress of clinical studies
BONE THERAPEUTICS the cell therapy company addressing unmet medical needs in orthopedics and other diseases provides an update on its two leading ongoing clinical studies.
These studies are the pivotal Phase III clinical trial with Bone Therapeutics’ enhanced viscosupplement, JTA-004, targeting osteoarthritic knee pain, and the Phase IIb study with its allogeneic cell therapy product, ALLOB, in patients with difficult-to-heal tibial fractures.